RxDoctor Payments Data

Jorge Robles, MD

Family Medicine · El Centro, CANPI 1366517716

Payments from drug & device makers

$258,918in general payments, 2019–2025

Across 1,068 payments — averaging $242.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$201K
  • Novo Nordisk$16K
  • Johnson & Johnson$10K
  • AstraZeneca$7K
  • Amarin Pharma, Inc.$5K
  • AbbVie$5K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$1,7353%
  • Speaking & faculty fees$35,81360%
  • Travel & lodging$1,0752%
  • Food & beverage$20,57335%
  • Education$1180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.13$200,964
Novo Nordisk137$15,863
Johnson & Johnson102$10,257
AstraZeneca99$6,788
Amarin Pharma, Inc.24$5,010
AbbVie(2 entities)98$4,782
Boston Scientific23$3,100
Boehringer Ingelheim33$1,644
Bayer46$1,154
Merck55$1,105
Radius Health, Inc.52$831
Corcept Therapeutics46$773
Amgen(2 entities)38$684
GSK30$625
Otsuka America Pharmaceutical, Inc.28$573
Novartis21$448
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)11$435
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$372
Sanofi-aventis U.S. LLC29$370
Lilly USA, LLC19$336
Astellas Pharma US Inc16$289
Medtronic(2 entities)8$263
Esperion Therapeutics, Inc.18$251
Kowa Pharmaceuticals America, Inc.12$192
Ironwood Pharmaceuticals, Inc9$153
Abbott8$147
Sanofi2$136
Pfizer8$129
Regeneron Healthcare Solutions, Inc.1$110
Shield Therapeutics Inc3$110
Dexcom, Inc.5$102
Sumitomo Pharma America, Inc.6$100
Insulet Corporation2$67
Xeris Pharmaceuticals, Inc.3$67
Lundbeck LLC2$51
Takeda Pharmaceuticals U.S.A., Inc.5$45
Nestle Healthcare Nutrition Inc.2$45
Eisai Inc.2$41
Smith+Nephew2$37
Biohaven Pharmaceuticals, Inc.2$37
Alnylam Pharmaceuticals Inc.2$35
Supernus Pharmaceuticals, Inc.2$33
ANI Pharmaceuticals, Inc.1$30
Sanofi Pasteur Inc.1$29
Bardy Diagnostics, Inc.2$29
Si-bone, Inc.1$24
Cequr Corporation1$24
Redhill Biopharma Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$21
Sun Pharmaceutical Industries Inc.1$21
Stryker1$19
Genentech USA, Inc.1$19
Neotract Inc.1$18
Sunovion Pharmaceuticals Inc.1$17
Gilead1$17
Nevro Corp.1$15
E.r. Squibb & Sons, L.L.C.1$15
Daiichi Sankyo Inc.1$14
Mannkind Corporation1$14
Philips North America LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,918 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$686,267
Medicare patients
801
Services billed
8,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin697$613,876
OzempicSemaglutide582$608,871
KorlymMifepristone14$559,903
FarxigaDapagliflozin Propanediol608$518,824
EliquisApixaban206$205,207
RybelsusSemaglutide138$203,749
TymlosAbaloparatide40$154,256
LinzessLinaclotide162$142,814
Tresiba Flextouch U-200Insulin Degludec240$129,654
EntrestoSacubitril/Valsartan120$116,918
JanuviaSitagliptin Phosphate115$114,445
XareltoRivaroxaban125$109,012
TradjentaLinagliptin119$95,004
TrulicityDulaglutide81$93,374
KerendiaFinerenone80$75,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$15,863$838,532740 claims
Boehringer IngelheimJardiance, Tradjenta$1,644$708,881816 claims
Corcept TherapeuticsKorlym$773$559,90314 claims
AstraZenecaFarxiga, Breztri Aerosphere$6,788$557,841653 claims
PfizerEliquis$129$205,207206 claims
AbbVieLinzess, Creon$4,782$163,981188 claims
Radius Health, Inc.Tymlos$831$154,25640 claims
Lilly USA, LLCTrulicity, Mounjaro$336$139,062121 claims
MerckJanuvia, Janumet$1,105$136,208141 claims
NovartisEntresto$448$116,918120 claims
Johnson & JohnsonXarelto$10,257$109,012125 claims
BayerKerendia$1,154$75,31680 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in El Centro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →